184 related articles for article (PubMed ID: 35890352)
1. Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine.
Short KK; Lathrop SK; Davison CJ; Partlow HA; Kaiser JA; Tee RD; Lorentz EB; Evans JT; Burkhart DJ
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890352
[TBL] [Abstract][Full Text] [Related]
2. Co-Delivery of Novel Synthetic TLR4 and TLR7/8 Ligands Adsorbed to Aluminum Salts Promotes Th1-Mediated Immunity against Poorly Immunogenic SARS-CoV-2 RBD.
Siram K; Lathrop SK; Abdelwahab WM; Tee R; Davison CJ; Partlow HA; Evans JT; Burkhart DJ
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250834
[TBL] [Abstract][Full Text] [Related]
3. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
4. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
5. Use of protective antigen of Bacillus anthracis as a model recombinant antigen to evaluate toll-like receptors 2, 3, 4, 7 and 9 agonists in mice using established functional antibody assays, antigen-specific antibody assays and cellular assays.
Inglefield J; Catania J; Harris A; Hickey T; Ma Z; Minang J; Baranji K; Spangler T; Look J; Ruiz C; Lu H; Alleva D; Reece JJ; Lacy MJ
Vaccine; 2022 Sep; 40(38):5544-5555. PubMed ID: 35773119
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
9. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
[TBL] [Abstract][Full Text] [Related]
10. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).
Baudner BC; Ronconi V; Casini D; Tortoli M; Kazzaz J; Singh M; Hawkins LD; Wack A; O'Hagan DT
Pharm Res; 2009 Jun; 26(6):1477-85. PubMed ID: 19255727
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
12. Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators.
Lodaya RN; Brito LA; Wu TYH; Miller AT; Otten GR; Singh M; O'Hagan DT
J Pharm Sci; 2018 Sep; 107(9):2310-2314. PubMed ID: 29883663
[TBL] [Abstract][Full Text] [Related]
13. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.
Grigoryan L; Lee A; Walls AC; Lai L; Franco B; Arunachalam PS; Feng Y; Luo W; Vanderheiden A; Floyd K; Wrenn S; Pettie D; Miranda MC; Kepl E; Ravichandran R; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; Coffman RL; Novack D; Kleanthous H; O'Hagan DT; van der Most R; McLellan JS; Suthar M; Veesler D; King NP; Pulendran B
NPJ Vaccines; 2022 May; 7(1):55. PubMed ID: 35606518
[TBL] [Abstract][Full Text] [Related]
14. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity.
Liao HC; Wu WL; Chiang CY; Huang MS; Shen KY; Huang YL; Wu SC; Liao CL; Chen HW; Liu SJ
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563292
[TBL] [Abstract][Full Text] [Related]
16. A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7.
Fox CB; Sivananthan SJ; Duthie MS; Vergara J; Guderian JA; Moon E; Coblentz D; Reed SG; Carter D
J Nanobiotechnology; 2014 Apr; 12():17. PubMed ID: 24766820
[TBL] [Abstract][Full Text] [Related]
17. Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine.
O'Donnell JS; Isaacs A; Jakob V; Lebas C; Barnes JB; Reading PC; Young PR; Watterson D; Dubois PM; Collin N; Chappell KJ
Front Immunol; 2022; 13():976968. PubMed ID: 36119058
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice.
Khan MS; Jakob V; Singh R; Rajmani RS; Kumar S; Lemoine C; Kleanthous H; Ringe RP; Dubois PM; Varadarajan R
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140101
[TBL] [Abstract][Full Text] [Related]
19. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
Del Giudice G; Rappuoli R; Didierlaurent AM
Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
